AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

58.60USD
1:32am IST
Price Change (% chg)

$0.67 (+1.16%)
Prev Close
$57.93
Open
$57.63
Day's High
$58.70
Day's Low
$57.46
Volume
1,547,336
Avg. Vol
1,966,627
52-wk High
$58.77
52-wk Low
$44.02

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a research-based pharmaceuticals company. The Company discovers, develops, and commercializes advanced therapies. AbbVie's portfolio of products include a line of adult and pediatric pharmaceuticals, which includes HUMIRA, metabolics/hormones products, virology products, endocrinology products, dyslipidem... (more)

Overall

Beta: --
Market Cap (Mil.): $92,191.53
Shares Outstanding (Mil.): 1,592.81
Dividend: 0.42
Yield (%): 2.90

Financials

  ABBV.N Industry Sector
P/E (TTM): 22.33 32.64 33.50
EPS (TTM): 2.59 -- --
ROI: 19.03 18.10 17.33
ROE: 95.03 18.80 18.19
Search Stocks

Deals of the day- Mergers and acquisitions

(Adds SABMiller, Orange, BNP Paribas, AbbVie, America Movil, Microsoft, Club Mediterranee, JSW Steel, Alere, GFI Group, AngloGold Ashanti, Qatar National Bank and Telekom)

16 Sep 2014

EU to decide on $52 billion AbbVie, Shire deal by Oct. 16

BRUSSELS - European Union competition regulators will decide by Oct. 16 whether to clear U.S. drugmaker AbbVie's 32 billion pounds (51.99 billion US dollar) bid for Irish peer Shire Plc , the European Commission said on Monday.

15 Sep 2014

UPDATE 2-AbbVie, Teva broke law in AndroGel "pay for delay" deal, U.S. says

WASHINGTON, Sept 8 - The U.S. Federal Trade Commission on Monday sued Drugmakers AbbVie Inc and Teva Pharmaceuticals Industries Ltd for allegedly illegally preventing generic versions of AndroGel, for men with low testosterone, from getting to market.

09 Sep 2014

US FTC says AbbVie, Teva broke law in reaching AndroGel agreement

WASHINGTON, Sept 8 - Drug companies AbbVie Inc and Teva Pharmaceuticals Industries Ltd were sued by the U.S. Federal Trade Commission on Monday for allegedly illegally preventing generic production of AndroGel, used by men with low testosterone.

08 Sep 2014

UPDATE 1-Ex-Genentech boss Levinson resigns from Roche's board

* Departure a "loss" for Roche - analyst (Amends slug, adds details on AbbVie Calico deal, analyst)

04 Sep 2014

Google's Calico, AbbVie forge deal against diseases of aging

- U.S. drugmaker AbbVie Inc and Calico, a new company set up by Google Inc to cure diseases of aging, will each invest $250 million to help create Calico research facilities and collaborate on discovery and development of new medicines.

04 Sep 2014

UPDATE 2-Google's Calico, AbbVie forge deal against diseases of aging

Sept 3 - U.S. drugmaker AbbVie Inc and Calico, a new company set up by Google Inc to cure diseases of aging, will each invest $250 million to help create Calico research facilities and collaborate on discovery and development of new medicines.

04 Sep 2014

Drug company won't appeal gay rights ruling to top U.S. court

SAN FRANCISCO, Aug 5 - AbbVie Inc will not seek U.S. Supreme Court review of a ruling in a lawsuit brought against the company that extended landmark constitutional protections for gays and lesbians, a company spokesman said on Tuesday.

06 Aug 2014

UPDATE 3-AbbVie profit beats estimates on surging Humira sales

July 25 - AbbVie Inc, which last week announced plans to buy Dublin-based drugmaker Shire Plc for $55 billion, reported stronger-than-expected quarterly earnings on surging sales of its Humira treatment for rheumatoid arthritis.

25 Jul 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $105.88 +1.16
Pfizer Inc. (PFE.N) $30.05 +0.13
Novartis AG (NOVN.VX) CHF87.75 -0.35
Merck & Co., Inc. (MRK.N) $59.99 +0.47
Roche Holding Ltd. (ROG.VX) CHF277.50 +1.70
Abbott Laboratories (ABT.N) $42.90 +0.18
Eli Lilly and Co (LLY.N) $65.80 +0.61

Earnings vs. Estimates

Search Stocks